title: Allogeneic hematopoietic stem cell transplantation in Tunisia.
abstract: In 1998, the Tunisian team of the 'Centre National de Greffe de Moelle Osseuse' initiated allogeneic hematopoietic SCT (AHSCT) in Tunisia. As of June 2007, information was collected about 299 patients with a first AHSCT and 12 additional retransplants. The median age was 19 years (range 2-49 years). The main indications were aplastic anemia (n=106, 36%), leukemia and nonmalignant disorders (n=153, 51%), Fanconi anemia (n=26, 9%) and other nonmalignant disorders (n=14, 4%). Preparative regimens depended on indication. All donors were HLA geno-identical. The stem cell sources were BM (87%) and PBSCs (13%). At the time of analysis, 200 patients (67%) were alive after a median follow-up of 42 months (range 3-112 months). The overall TRM rate was 17%. Outcome depended on indication. According to our results, allogeneic HSCT is potentially curative for hematological diseases, but it is a toxic approach for malignant disorders.
authors: Hematology Department, Centre National de Greffe de Moelle Osseuse de Tunis, Tunis, Tunisia. benothman-t@mailcity.com
authors: T
authors: T
authors: Ben Othman
authors: L
authors: L
authors: Torjemane
authors: A
authors: A
authors: Abdelkefi
authors: A
authors: A
authors: Lakhal
authors: S
authors: S
authors: Ladeb
authors: L
authors: L
authors: Ben Hamed
authors: H
authors: H
authors: Slama
authors: A
authors: A
authors: Ben Abdeladhim
mesh_terms: D018380:Hematopoietic Stem Cell Transplantation / Q000706:statistics & numerical data; D006801:Humans; D014019:Tissue Donors; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous; D014416:Tunisia